Literature DB >> 33352897

Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection.

Hannah Miller1,2, Zoltan Czigany2, Isabella Lurje2,3, Sophie Reichelt1,2, Jan Bednarsch2, Pavel Strnad4, Christian Trautwein4, Christoph Roderburg3,4, Frank Tacke3,4, Nadine Therese Gaisa5, Ruth Knüchel-Clarke5, Ulf Peter Neumann2, Georg Lurje1,2.   

Abstract

Tumor angiogenesis plays a pivotal role in hepatocellular carcinoma (HCC) biology. Identifying molecular prognostic markers is critical to further improve treatment selection in these patients. The present study analyzed a subset of 10 germline polymorphisms involved in tumor angiogenesis pathways and their impact on prognosis in HCC patients undergoing partial hepatectomy in a curative intent. Formalin-fixed paraffin-embedded (FFPE) tissues were obtained from 127 HCC patients at a German primary care hospital. Genomic DNA was extracted, and genotyping was carried out using polymerase chain reaction (PCR)-restriction fragment length polymorphism-based protocols. Polymorphisms in interleukin-8 (IL-8) (rs4073; p = 0.047, log-rank test) and vascular endothelial growth factor (VEGF C + 936T) (rs3025039; p = 0.045, log-rank test) were significantly associated with disease-free survival (DFS). After adjusting for covariates in the multivariable model, IL-8 T-251A (rs4073) (adjusted p = 0.010) and a combination of "high-expression" variants of rs4073 and rs3025039 (adjusted p = 0.034) remained significantly associated with DFS. High-expression variants of IL-8 T-251A may serve as an independent molecular marker of prognosis in patients undergoing surgical resection for HCC. Assessment of the patients' individual genetic risks may help to identify patient subgroups at high risk for recurrence following curative-intent surgery.

Entities:  

Keywords:  IL8; hepatocellular carcinoma; single-nucleotide polymorphism

Year:  2020        PMID: 33352897      PMCID: PMC7767259          DOI: 10.3390/cancers12123826

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

Review 1.  Tumor vessel normalization and immunotherapy in gastric cancer.

Authors:  Xianzhe Yu; Shan He; Jian Shen; Qiushi Huang; Peng Yang; Lin Huang; Dan Pu; Li Wang; Lu Li; Jinghua Liu; Zelong Liu; Lingling Zhu
Journal:  Ther Adv Med Oncol       Date:  2022-07-18       Impact factor: 5.485

2.  UDCA Inhibits Hypoxic Hepatocellular Carcinoma Cell-Induced Angiogenesis Through Suppressing HIF-1α/VEGF/IL-8 Intercellular Signaling.

Authors:  Wanfu Lin; Shu Li; Yongbin Meng; Guokai Huang; Shufang Liang; Juan Du; Qun Liu; Binbin Cheng
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

3.  The Role of Sarcopenia and Myosteatosis in Short- and Long-Term Outcomes Following Curative-Intent Surgery for Hepatocellular Carcinoma in a European Cohort.

Authors:  Franziska Alexandra Meister; Georg Lurje; Suekran Verhoeven; Georg Wiltberger; Lara Heij; Wen-Jia Liu; Decan Jiang; Philipp Bruners; Sven Arke Lang; Tom Florian Ulmer; Ulf Peter Neumann; Jan Bednarsch; Zoltan Czigany
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.